[go: up one dir, main page]

HRP20050045B1 - Derivati kvinolina i njihova upotreba kao inhibitora mikobakterija - Google Patents

Derivati kvinolina i njihova upotreba kao inhibitora mikobakterija

Info

Publication number
HRP20050045B1
HRP20050045B1 HRP20050045AA HRP20050045A HRP20050045B1 HR P20050045 B1 HRP20050045 B1 HR P20050045B1 HR P20050045A A HRP20050045A A HR P20050045AA HR P20050045 A HRP20050045 A HR P20050045A HR P20050045 B1 HRP20050045 B1 HR P20050045B1
Authority
HR
Croatia
Prior art keywords
compounds
hydrogen
quinoline derivatives
independently
pharmaceutically acceptable
Prior art date
Application number
HRP20050045AA
Other languages
English (en)
Inventor
Josef Frans Elisabetha Van Gestel
Jerome Emile Georges Guillemont
Marc Gaston Venet
Laurence Francoise Bernadette Decrane
Daniel F. J. Vernier
Frank Christopher Odds
Imre Christian Francis Csoka
Koenraad Jozef Lodewijk Marcel Andreis
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050045(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20050045A2 publication Critical patent/HRP20050045A2/hr
Publication of HRP20050045B1 publication Critical patent/HRP20050045B1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Ovaj izum odnosi se na nove supstituirane derivate kvinolina prema općenitoj formuli (Ia) ili općenitoj formuli (Ib), njihovih farmaceutski prihvatljivih soli nastalih dodavanjem kiselina ili lužina, njihovih stereokemijskih izomera, njihovih tautomernih oblika i njihovih N-oksida. Spojevi iz zahtjeva su korisni za tretman mikobakterijskih bolesti, narocito onih bolesti koje su izazvane patogenim mikobakterijama kao sto su Mycobacterium tuberculosis, M. bovis, M. avium i M. marinum. Preciznije, u patentnim zahtjevima su spojevi u kojima je, neovisno jedan od drugoga, R1 bromo, p=1, R2 je alkiloksi, R3 može biti supstituirani naftil ili fenil, q=1, R4 i R5 svaki neovisno od onog drugog može biti vodik, metil ili etil, R6 je vodik, r je jednak 0 ili 1 i R7 je vodik. U patentnim zahtjevima je također kompozicija koja obuhvaća farmaceutski prihvatljiv nosac i, kao aktivni sastojak, terapijski učinkovitu količinu navedenih spojeva, upotrebu ovih spojeva ili kompozicija za proizvodnju lijeka za tretman mikobakterijskih bolesti i postupak za pripremu istih spojeva.
HRP20050045AA 2002-07-25 2003-07-18 Derivati kvinolina i njihova upotreba kao inhibitora mikobakterija HRP20050045B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39871102P 2002-07-25 2002-07-25
PCT/EP2003/050322 WO2004011436A1 (en) 2002-07-25 2003-07-18 Quinoline derivatives and their use as mycobacterial inhibitors

Publications (2)

Publication Number Publication Date
HRP20050045A2 HRP20050045A2 (en) 2006-06-30
HRP20050045B1 true HRP20050045B1 (hr) 2013-09-30

Family

ID=31188461

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20120190AA HRP20120190B1 (hr) 2002-07-25 2003-07-18 Derivati kvinolina i njihova upotreba kao inhibitora mikobakterija
HRP20050045AA HRP20050045B1 (hr) 2002-07-25 2003-07-18 Derivati kvinolina i njihova upotreba kao inhibitora mikobakterija

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20120190AA HRP20120190B1 (hr) 2002-07-25 2003-07-18 Derivati kvinolina i njihova upotreba kao inhibitora mikobakterija

Country Status (37)

Country Link
US (1) US7498343B2 (hr)
EP (2) EP1527050B1 (hr)
JP (1) JP4484703B2 (hr)
KR (1) KR100733577B1 (hr)
CN (2) CN101070304B (hr)
AP (1) AP2421A (hr)
AR (1) AR040673A1 (hr)
AT (1) ATE463482T1 (hr)
AU (1) AU2003262529B2 (hr)
BE (1) BE2014C051I2 (hr)
BR (1) BRPI0312927B8 (hr)
CA (1) CA2493225C (hr)
CY (3) CY1111882T1 (hr)
DE (1) DE60332023D1 (hr)
DK (2) DK2301544T3 (hr)
EA (1) EA008937B1 (hr)
ES (2) ES2395237T3 (hr)
FR (1) FR14C0060I2 (hr)
HR (2) HRP20120190B1 (hr)
HU (1) HUS1400047I1 (hr)
IL (2) IL166457A (hr)
IS (1) IS2914B (hr)
LU (1) LU92520I2 (hr)
ME (1) ME00131B (hr)
MX (1) MXPA05001052A (hr)
MY (1) MY143564A (hr)
NL (1) NL300684I2 (hr)
NO (2) NO329935B1 (hr)
NZ (1) NZ538391A (hr)
PL (1) PL222801B1 (hr)
PT (2) PT1527050E (hr)
RS (1) RS52431B (hr)
SI (2) SI1527050T1 (hr)
TW (1) TWI323730B (hr)
UA (1) UA82198C2 (hr)
WO (1) WO2004011436A1 (hr)
ZA (1) ZA200500680B (hr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1909907B (zh) 2004-01-23 2010-06-23 詹森药业有限公司 喹啉衍生物及其在制备分枝杆菌抑制剂中的用途
US7338949B2 (en) * 2004-01-23 2008-03-04 Janssen Pharmaceutica N.V. Mycobacterial inhibitors
KR101160183B1 (ko) * 2004-01-29 2012-06-26 얀센 파마슈티카 엔.브이. 마이코박테리아 저해제로서 사용하기 위한 퀴놀린 유도체
ES2306146T3 (es) * 2004-05-28 2008-11-01 Janssen Pharmaceutica Nv Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a farmacos.
DK1797115T3 (en) 2004-09-28 2017-10-02 Janssen Pharmaceutica Nv BACTERIAL ATP SYNTHASE BINDING DOMAIN.
EA009779B1 (ru) * 2004-12-24 2008-04-28 Янссен Фармацевтика Н.В. Лечение латентного туберкулёза
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
RS52316B (en) * 2005-05-25 2012-12-31 Janssen Pharmaceutica Nv PREPARATION PROCESS (ALFA S, BETA R) -6-BROMO-ALFA- [2¬ (DIMETHYLAMINO) ETHYL] -2-METHOXY-ALPHA-1-NAPHTHALENYL-BETA-PHENYL-3-QUINOLINETHANOL
TWI380819B (zh) * 2005-06-08 2013-01-01 Janssen Pharmaceutica Nv 用作抗細菌劑之喹啉衍生物
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
EA010601B1 (ru) * 2005-06-09 2008-10-30 Янссен Фармацевтика Н.В. Производные хинолина в качестве антибактериальных агентов
KR101318181B1 (ko) * 2005-06-09 2013-10-16 얀센 파마슈티카 엔.브이. 항균제로서의 퀴놀린 유도체
JP5349730B2 (ja) * 2005-06-09 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としてのキノリン誘導体
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
WO2007000434A1 (en) * 2005-06-28 2007-01-04 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
JO3077B1 (ar) * 2005-07-28 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينولين مضادة للبكتيريا
JO2952B1 (en) * 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2855B1 (en) * 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2837B1 (en) * 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents
EP1917245A1 (de) * 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
DE102005044817A1 (de) 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO2685B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2683B1 (en) 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2684B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
CN102249935B (zh) * 2010-05-17 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 芳香2-丁醇类化合物及其医药用途
RU2486175C2 (ru) * 2011-09-12 2013-06-27 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений
PL2841426T3 (pl) 2012-04-27 2017-03-31 Janssen Pharmaceutica N.V. Przeciwbakteryjne pochodne chinoliny
JP6153604B2 (ja) 2012-04-27 2017-06-28 ヤンセン ファーマシューティカ エヌ．ベー． 抗菌性キノリン誘導体
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
MY173280A (en) 2012-12-21 2020-01-10 Janssen Sciences Ireland Uc Antibacterial compounds
RU2530493C1 (ru) * 2013-04-22 2014-10-10 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ их получения и применение соединений для лечения инфекционных заболеваний микобактериальной природы, в частности туберкулеза
CN105017147B (zh) * 2014-04-30 2019-02-01 中国医学科学院药物研究所 一种回收和利用Bedaquiline立体化学异构体的方法
CN105085395B (zh) * 2014-05-07 2017-09-26 国药集团国瑞药业有限公司 贝达喹啉的制备方法
CN105085396B (zh) * 2014-05-07 2017-08-08 国药集团国瑞药业有限公司 用于制备贝达喹啉的中间体及其制备方法和应用
CN105198808B (zh) * 2014-05-27 2017-08-25 北京万生药业有限责任公司 一种高效生产贝达喹啉的方法
CN105175329B (zh) * 2014-06-10 2017-09-19 重庆圣华曦药业股份有限公司 一种贝达喹啉消旋体的合成路线及方法
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
WO2016008381A1 (zh) * 2014-07-14 2016-01-21 辰欣药业股份有限公司 吡啶衍生物及其作为抗分支杆菌的应用
CN105440051B (zh) * 2014-09-19 2019-07-05 重庆医药工业研究院有限责任公司 一种抗结核的噻吩吡啶衍生物
CZ2014708A3 (cs) 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
CZ201533A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Způsob izolace směsi enantiomerů
CZ201534A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Nové možnosti chirální resoluce bedaquilinu
CZ201535A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Nové možnosti chirální resoluce bedaquilinu
ES2948805T3 (es) 2015-01-27 2023-09-19 Janssen Pharmaceutica Nv Composiciones dispersables
WO2016174673A1 (en) * 2015-04-29 2016-11-03 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Anti-phytopathogenic compositions
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
MX386598B (es) 2015-07-02 2025-03-19 Janssen Sciences Ireland Uc Compuestos antibacterianos.
CN105061387A (zh) * 2015-07-17 2015-11-18 苏州大学 二芳基醚类稠环类化合物、制备方法和用途
CN107848978B (zh) * 2015-07-24 2021-04-02 浙江海正药业股份有限公司 一种分离贝达喹啉非对映异构体a的方法
CN108349898B (zh) * 2015-10-20 2021-03-23 浙江海正药业股份有限公司 富马酸贝达喹啉的晶型及其制备方法
WO2017121323A1 (zh) * 2016-01-13 2017-07-20 辰欣药业股份有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
WO2017149551A1 (en) * 2016-03-03 2017-09-08 Council Of Scientific & Industrial Research Substituted aurone alkaloids as anti-mycobacterial agents
JP6997095B2 (ja) * 2016-03-07 2022-02-03 ザ グローバル アライアンス フォー ティービー ドラッグ デベロップメント， インコーポレイテッド 抗菌性化合物およびその使用
US20200308169A1 (en) 2016-06-16 2020-10-01 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
CA3026010A1 (en) 2016-06-16 2017-12-21 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
EP4417262A3 (en) 2017-03-01 2024-11-27 Janssen Sciences Ireland Unlimited Company Combination therapy
EP3943070B1 (en) 2017-07-14 2023-11-22 Janssen Pharmaceutica NV Long-acting formulations of bedaquiline
CN109384716B (zh) * 2017-08-11 2021-06-29 海创药业股份有限公司 一种氘代喹啉化合物及其制备和用途
CN113271930A (zh) 2019-01-09 2021-08-17 詹森药业有限公司 治疗非结核分枝杆菌疾病的组合
WO2020161743A1 (en) 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
BR112022003799A2 (pt) 2019-09-13 2022-05-24 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
CN112574175B (zh) * 2019-09-29 2023-11-14 南京长澳医药科技有限公司 喹啉类化合物、其制备方法和用途
EP4038067A1 (en) 2019-09-30 2022-08-10 Janssen Sciences Ireland Unlimited Company 4-quinolinone antibacterial compounds
BR112022005449A2 (pt) 2019-09-30 2022-06-21 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
CN110804016B (zh) * 2019-12-05 2022-11-04 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物
EP4081304B1 (en) 2019-12-27 2024-03-06 Tecnimede, Sociedade Técnico-Medicinal, SA Antibacterial quinolines
KR102303635B1 (ko) 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
WO2022008644A1 (en) 2020-07-09 2022-01-13 Janssen Pharmaceutica Nv Long-acting formulations
US20230241051A1 (en) 2020-07-09 2023-08-03 Janssen Pharmaceutica Nv Long-acting formulations
JP2023532982A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
KR20230107275A (ko) 2020-11-12 2023-07-14 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물
AU2022237769A1 (en) 2021-03-16 2023-11-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
BR112023018654A2 (pt) 2021-03-17 2023-10-03 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
CN117580843A (zh) 2021-03-17 2024-02-20 爱尔兰詹森科学公司 抗菌化合物
WO2022214520A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214519A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
MX2024000111A (es) 2021-06-29 2024-01-19 Tecnimede Sociedade Tecnico Medicinal Sa Compuestos heterociclicos para el tratamiento de tuberculosis.
CN118159543A (zh) 2021-10-28 2024-06-07 爱尔兰詹森科学公司 在治疗细菌感染中使用的咪唑并吡啶酰胺和相关化合物
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
CN114835641B (zh) * 2022-05-07 2024-03-15 南京杰运医药科技有限公司 一种3-苄基-6-溴-2-甲氧基喹啉的合成方法
CN117050006A (zh) * 2022-05-13 2023-11-14 广州嘉越医药科技有限公司 一种吡啶衍生物、中间体、制备方法和应用
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
AU2023382389A1 (en) 2022-11-15 2025-05-15 Eli Lilly And Company Ahr agonists
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025068448A1 (en) 2023-09-28 2025-04-03 Janssen Pharmaceutica Nv Atp synthase inhibitors for use in the treatment of non-tuberculosis mycobacteria

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037635A1 (en) * 1998-01-26 1999-07-29 Smithkline Beecham Plc Quinoline derivatives as antibacterials
US5965572A (en) * 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
WO2003004265A1 (en) * 2001-07-06 2003-01-16 Zygo Corporation Polymer retarder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU757059B2 (en) * 1997-06-19 2003-01-30 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
WO1999037365A1 (en) * 1998-01-23 1999-07-29 Fire Armour Pte Ltd. Nozzle with axially and perpendicularly directed apertures
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965572A (en) * 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
WO1999037635A1 (en) * 1998-01-26 1999-07-29 Smithkline Beecham Plc Quinoline derivatives as antibacterials
WO2003004265A1 (en) * 2001-07-06 2003-01-16 Zygo Corporation Polymer retarder

Also Published As

Publication number Publication date
ES2395237T3 (es) 2013-02-11
TWI323730B (en) 2010-04-21
JP2006504658A (ja) 2006-02-09
IL166457A0 (en) 2006-01-15
PL375523A1 (en) 2005-11-28
ATE463482T1 (de) 2010-04-15
KR100733577B1 (ko) 2007-06-29
EP2301544A1 (en) 2011-03-30
UA82198C2 (uk) 2008-03-25
KR20050033607A (ko) 2005-04-12
LU92520I2 (fr) 2015-11-02
AR040673A1 (es) 2005-04-13
HRP20050045A2 (en) 2006-06-30
TW200410939A (en) 2004-07-01
CY2014033I2 (el) 2016-04-13
IS2914B (is) 2014-12-15
ME00131B (me) 2010-10-10
IL166457A (en) 2011-10-31
EA008937B1 (ru) 2007-10-26
CN1671667A (zh) 2005-09-21
AU2003262529B2 (en) 2009-11-19
IS7620A (is) 2004-12-29
SI1527050T1 (sl) 2010-08-31
CA2493225C (en) 2012-03-20
US7498343B2 (en) 2009-03-03
EP1527050B1 (en) 2010-04-07
BRPI0312927B1 (pt) 2018-07-10
CN101070304B (zh) 2011-10-26
CY1113497T1 (el) 2016-06-22
CA2493225A1 (en) 2004-02-05
MY143564A (en) 2011-05-31
PT2301544E (pt) 2012-12-10
CY2014033I1 (el) 2016-04-13
BRPI0312927B8 (pt) 2021-05-25
EP1527050A1 (en) 2005-05-04
CY1111882T1 (el) 2015-11-04
MEP9208A (hr) 2010-06-10
EP2301544B1 (en) 2012-09-19
HRP20120190A2 (hr) 2012-05-31
CN101070304A (zh) 2007-11-14
JP4484703B2 (ja) 2010-06-16
BR0312927A (pt) 2005-07-12
EA200500257A1 (ru) 2005-06-30
MXPA05001052A (es) 2005-04-08
FR14C0060I2 (fr) 2015-11-20
NO2014021I1 (no) 2014-08-20
ES2343458T3 (es) 2010-08-02
HK1113795A1 (en) 2008-10-17
US20050148581A1 (en) 2005-07-07
NO2014021I2 (hr) 2014-08-20
HUS1400047I1 (hu) 2016-09-28
FR14C0060I1 (hr) 2014-10-10
RS20050058A (en) 2007-06-04
HRP20120190B1 (hr) 2017-06-02
DK2301544T3 (da) 2013-01-02
AP2005003210A0 (en) 2005-03-31
AP2421A (en) 2012-06-08
ZA200500680B (en) 2006-08-30
NO329935B1 (no) 2011-01-24
IL202655A (en) 2012-04-30
HRP20120190A8 (hr) 2012-07-31
NL300684I2 (hr) 2016-10-11
HK1083496A1 (en) 2006-07-07
NZ538391A (en) 2005-10-28
CN1325475C (zh) 2007-07-11
DE60332023D1 (de) 2010-05-20
NO20050476L (no) 2005-01-27
PL222801B1 (pl) 2016-09-30
DK1527050T3 (da) 2010-07-19
WO2004011436A1 (en) 2004-02-05
BE2014C051I2 (hr) 2022-08-09
PT1527050E (pt) 2010-06-22
SI2301544T1 (sl) 2013-01-31
RS52431B (en) 2013-02-28
AU2003262529A1 (en) 2004-02-16

Similar Documents

Publication Publication Date Title
HRP20050045B1 (hr) Derivati kvinolina i njihova upotreba kao inhibitora mikobakterija
EA200800455A1 (ru) Антибактериальные производные хинолина
JP2005502621A5 (hr)
MY140611A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
CA2536870A1 (en) Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
KR950704228A (ko) 선택적 포스포디에스테르가수분해효소 iv형(pde_iv) 저해제로서의 카테콜 디에테르(catecol diethers as selective pde_iv inhibitors)
ME00586A (en) Fungicidal azocyclic amides
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
NO20063747L (no) Substituerte kinoliner og deres anvendelse som mykobakterielle inhibitorer
MX2022011431A (es) Compuesto de oxazolidinona y metodos de uso de este como agente antibacteriano.
NO331174B1 (no) Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som neurokininantagonister
ZA202203107B (en) Azaindole carboxamide compounds for the treatment of mycobacterial infections
DE60226971D1 (de) Corticotropinfreisetzungsfaktor antagonisten
AR127955A1 (es) Nuevos compuestos heterocíclicos
ATE485822T1 (de) Phenylaminopyridine und phenylaminopyrazine
MEP61108A (en) Imidazolidine derivatives, their preparation, and their use as antinflamatory agent.
CY1112166T1 (el) Παραγωγο αζολιου χρησιμο ως αντιμυκητιακοι παραγοντες με μειωμενη αλληλεπιδραση με μεταβολικα κυτοχρωματα
PE20060698A1 (es) Formas cristalinas de un inhibidor del factor xa
TH86245B (th) ตัวยับยั้งที่เป็นแมโครไซคลิคของไวรัสตับอักเสบ c

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190624

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200713

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210716

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20220715

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20230718